Eyepoint Pharmaceuticals (EYPT) News Today $11.83 +0.23 (+1.98%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$11.87 +0.04 (+0.35%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Pass Above 200-Day Moving Average - Here's What HappenedAugust 23 at 4:26 AM | marketbeat.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 18, 2025 | globenewswire.comEyePoint Pharma’s Earnings Call: Clinical Wins Amid Financial ChallengesAugust 16, 2025 | theglobeandmail.comEyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic RetinopathyAugust 16, 2025 | msn.comXTX Topco Ltd Acquires New Stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT)August 14, 2025 | marketbeat.comAnalysts Have Lowered Expectations For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Its Latest ResultsAugust 9, 2025 | finance.yahoo.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Given Buy Rating at Chardan CapitalAugust 8, 2025 | marketbeat.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Expected to Rise, HC Wainwright Analyst SaysAugust 7, 2025 | marketbeat.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down on Disappointing EarningsAugust 7, 2025 | marketbeat.comEyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To ExpectAugust 7, 2025 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comEyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | globenewswire.comEyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate DevelopmentsAugust 6, 2025 | globenewswire.comFederated Hermes Inc. Has $22.14 Million Stock Holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT)August 2, 2025 | marketbeat.comEyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comEyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by BrokeragesJuly 31, 2025 | marketbeat.comEyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | globenewswire.comEyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular DegenerationJuly 29, 2025 | finanznachrichten.deEyePoint Completes Enrollment for Phase 3 TrialsJuly 29, 2025 | msn.comEyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular DegenerationJuly 29, 2025 | globenewswire.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?July 23, 2025 | marketbeat.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 16, 2025 | globenewswire.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Cross Above 200 Day Moving Average - What's Next?July 15, 2025 | marketbeat.comEYPT interactive stock chart | EyePoint Pharmaceuticals, Inc. stock - Yahoo FinanceJuly 12, 2025 | au.finance.yahoo.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5% - What's Next?July 11, 2025 | marketbeat.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 11% - Here's WhyJuly 9, 2025 | marketbeat.comEyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from AnalystsJuly 6, 2025 | marketbeat.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Pass Above 200 Day Moving Average - Time to Sell?July 5, 2025 | marketbeat.comEYPT EyePoint Pharmaceuticals, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 8.2% - Here's WhyJune 26, 2025 | marketbeat.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 9.3% - Here's WhyJune 24, 2025 | marketbeat.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5% - Should You Sell?June 20, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For EyePoint PharmaceuticalsJune 17, 2025 | benzinga.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - What's Next?June 17, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at Royal Bank of CanadaJune 17, 2025 | marketbeat.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 16, 2025 | globenewswire.comEyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026June 12, 2025 | seekingalpha.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 2.8% - Time to Sell?June 11, 2025 | marketbeat.comBrokers Set Expectations for EYPT FY2026 EarningsJune 10, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Principia Wealth Advisory LLCJune 7, 2025 | marketbeat.comBreakout Momentum Plays You May Not Know AboutMomentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.June 6, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 9.2% - Here's What HappenedJune 4, 2025 | marketbeat.comTwo Sigma Advisers LP Decreases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)June 3, 2025 | marketbeat.comShort Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 28.4%June 2, 2025 | marketbeat.comTwo Sigma Investments LP Sells 103,098 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)June 1, 2025 | marketbeat.comMillennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)June 1, 2025 | marketbeat.comEyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho SecuritiesMay 31, 2025 | theglobeandmail.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 21.2% - Still a Buy?May 30, 2025 | marketbeat.comEyePoint Pharmaceuticals' (EYPT) Buy Rating Reiterated at HC WainwrightMay 30, 2025 | marketbeat.comBank of America Corp DE Acquires 145,065 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)May 30, 2025 | marketbeat.com Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.870.68▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼24▲EYPT Articles Average Week Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXG News TRNS News ALNT News AEHR News CTKB News LAB News SENS News FEIM News MASS News QSI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access